SICHUAN HUIYU PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.11 CNY | +1.07% |
|
-2.69% | -6.74% |
| May. 15 | China Grants Drug Registration for Huiyu Pharma's Two Injectables | MT |
| Apr. 26 | Sichuan Huiyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Sichuan Huiyu Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of anti-tumor and injection drugs. The Companyâs products are mainly anti-tumor chemical injections, including pemetrexed disodium for injection, docetaxel injection, zoledronic acid injection, irinotecan hydrochloride injection, doxorubicin hydrochloride injection liquid and azacitidine for injection. The Company's products are mainly used in the clinical treatment of various adaptive diseases. The Company distributes its products both in the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.74% | 819M | |
| +32.20% | 694B | |
| +29.39% | 593B | |
| -1.61% | 371B | |
| +19.85% | 331B | |
| +6.60% | 290B | |
| +13.91% | 239B | |
| -3.15% | 209B | |
| +9.84% | 209B | |
| +7.88% | 169B |
- Stock Market
- Equities
- 688553 Stock
- News Sichuan Huiyu Pharmaceutical Co., Ltd.
- Huiyu Pharmaceutical's Subsidiary Administers First Patient for Tumor Drug Trial; Shares Drop 5%